The FDA approved letermovir (Prevymis, Merck) for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
Letermovir is a member of a new class of nonnucleoside CMV inhibitors (3,4-dihydroquinazolines) and inhibits viral replication by specifically targeting the viral terminase complex. Cross-resistance is not likely with drugs outside of this class.
The recommended dosage of letermovir